Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: Results of a randomized placebo-controlled trial cohort from China where endemicity is high

Vaccine

Volumn 29, Issue 12, 2011, Pages 2302-2307

  Wu, Qian ^a   Zhuang, Gui Hua ^a   Wang, Xue Liang ^a   Wang, Li Rong ^a   Li, Na ^a   Zhang, Min ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Anti HBs; Booster; Hepatitis B vaccine; Immune memory

Indexed keywords

HEPATITIS B VACCINE; PLACEBO; RECOMBINANT VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHILD; CHINA; CONTROLLED STUDY; ENDEMIC DISEASE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHOOL CHILD; SEROCONVERSION; VACCINATION;

ADULT; CHINA; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79951809574     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.025     Document Type: Article

References (28)

1. Chien Y.C., Jan C.F., Kuo H.S., Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006, 28:126-135.
2. Chang M.H., Chen T.H., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 2005, 11(21):7953-7957.
3. Chongsrisawat V., Yoocharoen P., Theamboonlers A., Tharmaphornpilas P., Warinsathien P., Sinlaparatsamee S., et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006, 11(10):1496-1502.
4. Zanetti A.R., Van Damme P., Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008, 26(49):6266-6273.
5. Liang X., Bi S., Yang W., Wang L., Cui G., Cui F., et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27(47):6550-6557.
6. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 2000, 355(9203):561-565.
7. Fitzsimons D., François G., Hall A., McMahon B., Meheus A., Zanetti A., et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005, 23(32):4158-4166.
8. Lu C.Y., Ni Y.H., Chiang B.L., Chen P.J., Chang M.H., Chang L.Y., et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008, 197(10):1419-1426.
9. Bialek S.R., Bower W.A., Novak R., Helgenberger L., Auerbach S.B., Williams I.T., et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008, 27(10):881-885.
10. Samandari T., Fiore A.E., Negus S., Williams J.L., Kuhnert W., McMahon B.J., et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007, 120(2):e373-e381.
11. Hammitt L.L., Hennessy T.W., Fiore A.E., Zanis C., Hummel K.B., Dunaway E., et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007, 25(39-40):6958-6964.
12. Poovorawan Y., Chongsrisawat V., Theamboonlers A., Bock H.L., Leyssen M., Jacquet J.M. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010, 28(3):730-736.
13. But D.Y., Lai C.L., Lim W.L., Fung J., Wong D.K., Yuen M.F. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008, 26(51):6587-6591.
14. McMahon B.J., Dentinger C.M., Bruden D., Zanis C., Peters H., Hurlburt D., et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009, 200(9):1390-1396.
15. Xu H.W., Li D.S., Xu J.W., Wang X.L., Men B.Y., Zheng Q.Q., et al. Evaluation of long-term efficacy on plasma-derived hepatitis B vaccine. Chin J Epidemiol 1992, 13(6):362-365.
16. Xu H.W., Zhuang G.H., Wang X.L., Chen Q.J., Chen Z.J. Efficacy and immune memory of plasma-derived hepatitis B vaccine 11 years after primary immunization. Chin J Prevent Med 2000, 34(2):113-115.
17. Moyer L.A., Mast E.E. Hepatitis A through E. J Intraven Nurs 1998, 21(5):286-290.
18. Lu C.Y., Chiang B.L., Chi W.K., Chang M.H., Ni Y.H., Hsu H.M., et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004, 40(6):1415-1420.
19. Whittle H., Jaffar S., Wansbrough M., Mendy M., Dumpis U., Collinson A., et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Br Med J 2002, 325(7364):569.
20. Wu J.S., Hwang L.Y., Goodman K.J., Beasley R.P. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis 1999, 179(6):1319-1325.
21. Coursaget P., Leboulleux D., Soumare M., le Cann P., Yvonnet B., Chiron J.P., et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol 1994, 21(2):250-254.
22. Lu C.Y., Chang M.H. Hepatitis B immunization: is a booster necessary?. Hepatitis B Annu 2005, 2(1):56-73.
23. Coates T., Wilson R., Patrick G., André F., Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001, 23(3):392-403.
24. Keating G.M., Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003, 63(10):1021-1051.
25. Poorolajal J., Mahmoodi M., Majdzadeh R., Nasseri-Moghaddam S., Haghdoost A., Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010, 28(3):623-631.
26. Shouval D. Hepatitis B vaccines. J Hepatol 2003, 39(Suppl 1):S70-S76.
27. Kao J.T., Wang J.H., Hung C.H., Yen Y.H., Hung S.F., Hu T.H., et al. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine 2009, 27(12):1858-1862.
28. Dentinger C.M., McMahon B.J., Butler J.C., Dunaway C.E., Zanis C.L., Bulkow L.R., et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 2005, 24(9):786-792.